Longer-term support holds AstraZeneca stock as price pulls back 2.01%

Traders Union
All News
Financial News
AstraZeneca drops 2.01% today

Highlights

AstraZeneca's obesity pill achieved 11.8% weight loss in mid-stage trials, underscoring competitive efficacy in the obesity market.
The company pledged $50 billion to expand its US infrastructure and reported strong Phase 3 results for Ultomiris in kidney disease.
AZN/GBX trades under short-term moving averages but maintains a bullish long-term trend, with high probability of an upward price move between GBX12,404.04 and GBX14,759.96.

Obesity drug trial success and US expansion amid ongoing selling pressure

AstraZeneca's experimental obesity pill demonstrated significant efficacy in mid-stage clinical trials, with patients achieving 11.8% and 10.5% weight loss over 36 and 26 weeks respectively, as reported by Bloomberg and Reuters. The company also committed $50 billion to expand its US research, manufacturing, and patient access footprint, as noted by yahoo.com, while Ultomiris showed a 46.6% reduction in proteinuria in a Phase 3 interim analysis for immunoglobulin A nephropathy, according to benzinga.com. CEO Pascal Soriot cited the increasing role of AI in enhancing drug development and clinical trial outcomes, as highlighted by businesschief.com and healthcare-digital.com, though price action has remained under broader selling pressure.

Diverging momentum signals as AZN trades near technical support

AZN/GBX recently closed below the MA-20 but above both the MA-50 (hourly) and the long-term MA-200, creating an alignment where immediate support from the Ichimoku Kijun sits at GBX12,621.00. The MACD indicator is at Strong Buy, while the ADX signals Sell, showing a divergence between rising momentum and weak trend strength; both RSI and Stoch RSI report strong buying conditions, whereas CCI remains in Buy territory. Bull/Bear Power indicates an Overbought environment intraday, with Awesome Oscillator neutral and low intraday volatility prevailing.

Range-bound outlook with breakout risk as volatility band narrows

In the short term, AZN is expected to fluctuate within a volatility band of GBX12,404.04 to GBX14,759.96. The highest probability scenario points to the price remaining range-bound between these support and resistance thresholds. Should momentum build, a breakout above the upper range could trigger further gains, while a breach below the Kijun support would signal greater downside risk.

Anton Kharitonov, expert at Traders Union, sees AstraZeneca’s strong drug pipeline and major US investment as supportive, but notes mixed technical signals and persistent short-term selling pressure. The alignment of moving averages, overbought intraday signals, and low volatility suggests a lack of clear directional conviction. He remains cautious given the volatile range and divergence between momentum and trend strength. "Until GBX14,759.96 is convincingly broken, I stay defensive and do not chase the upside here."

Previously it was reported that AstraZeneca's technical resilience and product pipeline advancements positioned the stock for a bullish setup. The latest clinical breakthroughs and ramped-up US investment strengthen this view, with current price action signaling the importance of monitoring momentum shifts for a potential breakout from range-bound trading.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.